NCT04224922 - Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

May 31, 2017

Conditions

Breast Cancer

Interventions

DRUG

Paclitaxel

DRUG

Carboplatinum

DRUG

Epirubicin

DRUG

Cyclophosphamide

Trial Locations (18)

1000

Institut Jules Bordet, Brussels

1340

Clinique st Pierre, Ottignies

2650

Universitaire Ziekenhuis Antwerpen, Edegem

2820

Imelda Ziekenhuis, Bonheiden

2930

AZ klina, Brasschaat

3000

UZ Leuven, Leuven

4000

CHR Citadelle, Liège

CHU Sart-Tilman, Liège

4800

CHR Verviers, Verviers

5000

CMSE, Namur

5530

CHU Mont-Godinne, Yvoir

6700

Cliniques Sud Luxembourg, Arlon

7500

CHWAPI, Tournai

8310

St Lucas, Bruges

8500

AZ Groeninge, Kortrijk

9000

AZ Maria Middelares, Ghent

AZ St Lucas, Ghent

9300

Onze Lieve Vrouw Ziekenhuis, Aalst

All Listed Sponsors

collaborator

Universitaire Ziekenhuizen KU Leuven

OTHER

collaborator

Universitair Ziekenhuis Brussel

OTHER

lead

AZ-VUB

OTHER